Trial Profile
ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Cenicriviroc (Primary)
- Indications Non-alcoholic fatty liver disease; Prediabetic state; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms ORION
- Sponsors Tobira Therapeutics
- 17 Aug 2017 Status changed from active, no longer recruiting to completed.
- 03 May 2016 Planned End Date changed from 1 Jun 2016 to 1 Sep 2016.
- 03 May 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Sep 2016.